Metabolic changes in cimetidine treatment for scald injury on the peritoneo-serosal surface in far-advanced gastric cancer patients treated by intraperitoneal hyperthermic perfusion.
Since pretreatment with cimetidine results in the prevention of scald injury on the peritoneo-serosal surface caused by intraperitoneal hyperthermic perfusion (IPHP) for advanced gastric cancer, the diverse influence of IPHP on patients who were either given or not given cimetidine was studied both during and after IPHP treatment. Cimetidine 50 mg/kg was injected intravenously into 12 patients immediately prior to IPHP. There were no statistical background differences between the cimetidine and control groups (those not given cimetidine). The inflow and outflow temperatures of the hyperthermic perfusate in the control and cimetidine groups were 46.1 +/- 0.1 degree C and 44.1 +/- 0.1 degree C and 46.3 +/- 0.1 degree C and 44.2 +/- 0.04 degree C, respectively. Either the pre-IPHP hypothermia or IPHP in the control group resulted in a considerable increase in serum noradrenaline and adrenaline. The intravenous administration of cimetidine led to a stransient but moderate drop in the mean blood pressure as well as a delayed appearance of high concentrations of noradrenaline and adrenaline, induced by high concentrations of circulating histamine released with cimetidine. These results suggest that the sympathetic nervous responses were activated either by hypothermia or hyperthermia. The transient hypotension and delayed increases of both serum catecholamines were attributed to a marked increase in circulating histamine, released with the intravenous cimetidine.
Fujimoto
S
S
Social Insurance Funabashi Central Hospital, Japan.
Takahashi
M
M
Kobayashi
K
K
Kokubun
M
M
Shrestha
R D
RD
Kiuchi
S
S
Konno
C
C
D001794:Blood Pressure / Q000187:drug effects; D002056:Burns / Q000209:etiology / Q000517:prevention & control*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects*; D002927:Cimetidine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004837:Epinephrine / Q000097:blood; D005260:Female; D005743:Gastrectomy; D006632:Histamine / Q000097:blood; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D010537:Peritoneum / Q000293:injuries*; D013274:Stomach Neoplasms / Q000097:blood* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*
D002927:Cimetidine; D006632:Histamine; D009638:Norepinephrine; D004837:Epinephrine